Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

89Bio Inc (NQ: ETNB )

9.140 +0.240 (+2.70%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 89Bio Inc

< Previous 1 2 3 4 5 6 7 8 Next >
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
First FGF21 analog to enter Phase 3 development 
From 89bio, Inc.
Via GlobeNewswire
Analyst Ratings for 89bio
Via Benzinga
89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
3 Biotech Buyout Targets to Watch
The trio all have late-stage therapies with blockbuster potential. 
Via The Motley Fool
89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/19
Via Investor Brand Network
89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/10
Via Investor Brand Network
89Bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 3/31
Via Investor Brand Network
Over $40M Bet On 89bio? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
89Bio Inc. (NASDAQ: ETNB) Records 52-Week High Friday Morning
Via Investor Brand Network
Why Shares of 89bio Soared This Week
The company released positive results for its lead therapy. 
Via The Motley Fool
89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock
From 89bio, Inc.
Via GlobeNewswire
89Bio Inc. (NASDAQ: ETNB) Near the Top of Equities by Percentage Gain on 3/22
Via Investor Brand Network
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023. 
Via Benzinga
KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
89bio To Rally 265%? Here Are 10 Other Analyst Forecasts For Thursday
Baird cut the price target for Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) from $14 to $11. Baird analyst Justin Kleber maintained an Outperform rating. Petco Health and Wellness shares rose... 
Via Benzinga
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
Dow Rises 75 Points; Fed Increases Rates By 25bps
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 75 points on Wednesday. The Dow traded up 0.23% to 32,635.71 while the NASDAQ rose 0.65% to 11,932.62. The S&P... 
Via Benzinga
Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why 89bio Shares Are Trading Higher Today
89bio (NASDAQ: ETNB) shares are trading higher on Wednesday after the company's Phase 2b ENLIVEN trial of pegozafermin in NASH achieved statistical significance on both primary histology endpoints. 
Via Benzinga
Nasdaq Edges Higher; Crude Oil Rises 1%
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite moving higher on Wednesday. The Dow traded down 0.15% to 32,512.83 while the NASDAQ rose 0.13% to 11,875.36. The S&P 500, also... 
Via Benzinga
89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)
89bio, Inc. (NASDAQ: ETNB) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development of 
Via Spotlight Growth
Exposures Product Safety
Why Are Meme Stocks GME, AMC, BBBY Up Today?
Meme stocks are on the move Wednesday as investors celebrate a recent earnings report from GameStop (GME) with a surprise profit. 
Via InvestorPlace
Travelzoo, Semler Scientific, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly higher, with the Dow Jones gaining around 20 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
SSYS Stock Alert: Stratasys Rejects Nano Dimension’s Takeover Offer
Stratasys (SSYS) stock is on the move Wednesday after the company rejected a $1.1 billion takeover offer from Nano Dimension. 
Via InvestorPlace
US Stocks Edge Lower Ahead Of Fed Decision; Nike Earnings Top Estimates
U.S. stocks traded slightly lower this morning. The Federal Reserve is scheduled to conclude a two-day policy meeting today, with markets expecting a 25 basis-point rate hike. Following the market... 
Via Benzinga
LAZR Stock Price Predictions: Why This Analyst Says Luminar Is Worth Just $5
Luminar (LAZR) stock is taking a beating on Wednesday as a new rating and price prediction weigh on the company's shares. 
Via InvestorPlace
Why Is 89bio (ETNB) Stock Up 34% Today?
89bio (ETNB) stock is taking off on Wednesday after the company posted results from a Phase 2b clinical trial of pegozafermin. 
Via InvestorPlace
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
The battle pits 89bio and Akero in nonalcoholic steatohepatitis. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.